Alimera Sciences News

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners

GlobeNewswireJun 4 16:30 ET

Express News | HC Wainwright & Co. Reiterates Buy on Alimera Sciences, Maintains $6 Price Target

BenzingaMay 16 07:08 ET

Alimera Sciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 76.99% HC Wainwright & Co. → $6 Reiterates Buy → Buy 03/25/2024 194.99% Maxim Group → $10 Initi

BenzingaMay 16 07:07 ET

Robust Growth and Promising Trials: Buy Rating for Alimera Sciences

TipRanksMay 16 06:28 ET

Alimera Sciences: A Strong Buy on Robust Q1 Growth, Strategic Acquisitions, and Positive Financial Indicators

TipRanksMay 15 12:25 ET

Alimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...

Yahoo FinanceMay 15 03:06 ET

Earnings Call Summary | Alimera Sciences(ALIM.US) Q1 2024 Earnings Conference

The following is a summary of the Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript:Financial Performance:Alimera Sciences reported a Q1 2024 consolidated global net revenue of $23 millio

moomoo AIMay 14 17:50 ET · Conference Call

Alimera Sciences | 10-Q: Quarterly report

SEC announcementMay 14 17:10 ET · Announcements

Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript

Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 14 13:40 ET

Alimera Sciences Confidence in Ability to Achieve $105 M in Rev and at Least 20% EBITDA Margins This Yr >ALIM

Alimera Sciences Confidence in Ability to Achieve $105 M in Rev and at Least 20% EBITDA Margins This Yr >ALIM

Dow JonesMay 14 07:34 ET

Express News | Alimera Sciences Inc - Reiterates Improved 2024 Net Revenue and Adjusted Ebitda Guidance

ReutersMay 14 07:31 ET

Express News | Alimera Sciences Reports First Quarter 2024 Results

ReutersMay 14 07:30 ET

Express News | Alimera Sciences, Inc. Q1 Net Income USD -6.251 Million

ReutersMay 14 07:30 ET

Express News | Alimera Sciences, Inc. Q1 Operating Expenses USD 21.96 Million

ReutersMay 14 07:30 ET

Alimera Sciences 1Q Loss/Shr 12c >ALIM

Alimera Sciences 1Q Loss/Shr 12c >ALIM

Dow JonesMay 14 07:30 ET

Express News | Alimera Sciences, Inc. Q1 Gross Profit USD 19.658 Million

ReutersMay 14 07:30 ET

Express News | Alimera Sciences, Inc. Q1 Net Revenue USD 23.011 Million Vs. Ibes Estimate USD 22.3 Million

ReutersMay 14 07:30 ET

Express News | Alimera Sciences, Inc. Q1 Income From Operations USD -2.302 Million

ReutersMay 14 07:30 ET

Alimera Sciences Q1 2024 Earnings Preview

Seeking AlphaMay 13 13:39 ET

Alimera Announces Scientific Data Highlighting YUTIQ to Be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners co

GlobeNewswireMay 7 08:00 ET